---
title: "Nexalin Technology, Inc. (NXL.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NXL.US.md"
symbol: "NXL.US"
name: "Nexalin Technology, Inc."
industry: "Health Care Equipment"
---

# Nexalin Technology, Inc. (NXL.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | US Market |
| Website | [www.nexalin.com](https://www.nexalin.com) |

## Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:12.000Z

**Overall: D (0.62)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 143 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.18% |  |
| Net Profit YoY | -56.25% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.77 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8.44M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 156931.00 |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -178.46% | E |
| Profit Margin | -5530.40% | E |
| Gross Margin | 78.25% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.18% | D |
| Net Profit YoY | -56.25% | D |
| Total Assets YoY | -2.50% | D |
| Net Assets YoY | -3.82% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1.81% | D |
| OCF YoY | -3.18% | D |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.03 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 6.97% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Nexalin Technology, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-178.46%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-5530.40%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "78.25%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.18%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-56.25%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.50%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.82%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1.81%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-3.18%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "6.97%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A |
| 02 | Delcath (US.DCTH) | C | A | A | A | A | A |
| 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B |
| 04 | Stryker (US.SYK) | A | B | C | C | B | B |
| 05 | Boston Scientific (US.BSX) | B | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.97 | 80/181 | - | - | - |
| PB | 1.77 | 50/181 | 7.64 | 4.38 | 2.63 |
| PS (TTM) | 53.79 | 136/181 | 157.05 | 129.55 | 84.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-08-19T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 1 | 100% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.45 |
| Highest Target | 4.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/NXL.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NXL.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NXL.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.